News
Public · Published
Harmony Biosciences Q3 revenue misses estimates, profit falls on royalty charges
Harmony Biosciences said third-quarter product revenue rose 12% year over year but missed analyst expectations. Pretax profit also missed estimates, while net income declined year over year as milestone and royalty charges increased.
Published:
Updated:
What happened
Harmony Biosciences said third-quarter product revenue rose 12% year over year but missed analyst expectations. Pretax profit also missed estimates, while net income declined year over year as milestone and royalty charges increased.
Confirmed
Global impact / market context
Revenue growth indicates stronger demand for WAKIX, which the company linked to 400 net patient additions and expanded sales and patient-support teams. But higher royalties raised product costs, while weaker-than-expected revenue and pretax profit show that growth did not prevent pressure on earnings.
Analyst inference
The results present a mixed picture for investors: demand and product revenue grew, yet both revenue and pretax profit fell short of analyst estimates. Harmony reiterated its 2026 WAKIX revenue outlook, so the key question is whether growth can offset rising royalty costs.
Analyst inference
What to watch
- Track WAKIX revenue and patient additions in coming quarters to assess whether the reported growth continues and supports the company's longer-term sales outlook. Analyst inference
- Watch how Novitium-related royalties affect product costs and earnings; the company said these new royalties were the main reason product costs increased. Confirmed
- Follow progress against the reiterated 2026 WAKIX revenue guidance, and whether patient demand continues to support that outlook as the company expands commercial teams. Confirmed
Evidence
- Original source link unavailable